RHOBTB2 Antibody

What is the basic structure and function of RHOBTB2?

RHOBTB2 belongs to the Rho GTPases subfamily of signaling proteins, consisting of RHOBTB1, RHOBTB2, and RHOBTB3. Its structure includes:

• A Rho GTPase domain

• A proline-rich region

• Two BTB domains (important for protein-protein interactions)

• A C-terminal region

RHOBTB2 acts as a molecular switch, shifting between active (GTP-bound) and inactive (GDP-bound) states. Unlike typical Rho GTPases, no specific guanine nucleotide exchange factors or activating factors are known to interact with RHOBTB2 .

The primary function of RHOBTB2 involves recruiting specific proteins to the cullin 3-dependent ubiquitin ligase complex (Cul3) for ubiquitination and subsequent degradation by the 26S proteasome. This occurs through its first BTB domain, which facilitates binding to Cul3 .

Where is RHOBTB2 primarily expressed in tissues?

RHOBTB2 shows tissue-specific expression patterns. Evidence suggests it is:

• Primarily expressed in neural tissues

• Also expressed, to a lesser extent, in fetal tissues including the lungs, heart, and brain

• Present in cell cortex, cell projections, cytoplasmic vesicles, cytoskeleton, and plasma membrane regions at the cellular level

This neural-predominant expression pattern correlates with its involvement in neurological disorders when mutated.

What criteria should be considered when selecting a RHOBTB2 antibody for research?

When selecting a RHOBTB2 antibody, researchers should consider:

• Target specificity: Ensure the antibody specifically detects endogenous levels of RHOBTB2 without cross-reactivity to related proteins like RHOBTB1 or RHOBTB3

• Epitope location: Choose antibodies targeting different regions (e.g., GTPase domain vs. BTB domains) depending on your research question

• Validated applications: Confirm the antibody has been validated for your intended application (WB, IHC, ICC, ELISA)

• Species reactivity: Verify compatibility with your experimental model (human, mouse, rat)

• Validation data: Review existing validation data, such as knockout controls, to ensure specificity

For instance, the rabbit polyclonal antibody described in the search results (CAB18432) has been validated for WB, IF/ICC, and ELISA applications, with specificity for human, mouse, and rat samples. It targets a sequence corresponding to amino acids 320-480 of human RHOBTB2 (NP_001153508.1) .

How can I validate a RHOBTB2 antibody in my experimental system?

Methodical validation of RHOBTB2 antibodies should include:

• Positive controls: Use tissues/cells known to express RHOBTB2 (e.g., rat lung, neural tissues)

• Negative controls:

  • Use RHOBTB2 knockout or knockdown cells (shRNA-based approaches targeting different regions have been described)

  • Omit primary antibody in parallel experiments

• Peptide competition: Pre-absorb the antibody with the immunizing peptide to confirm specificity

• Multiple antibody comparison: Compare results with antibodies targeting different epitopes of RHOBTB2

• Molecular weight verification: RHOBTB2 should appear at approximately 83 kDa in Western blots

• Subcellular localization: Verify that staining patterns match known RHOBTB2 distribution (cell cortex, cytoplasmic vesicles, plasma membrane)

In studies described in the search results, researchers validated antibody specificity by confirming protein levels increased after proteasome inhibitor (MG-132) treatment, consistent with RHOBTB2's known regulation .

What are the optimal conditions for Western blot detection of RHOBTB2?

For optimal Western blot detection of RHOBTB2:

• Sample preparation:

  • Use fresh protein lysates from tissues/cells expressing RHOBTB2

  • Add proteasome inhibitors (e.g., MG-132 at 5-25 μM for 4-16 hours) to increase detection sensitivity

  • Extract proteins using appropriate buffers (e.g., 100 mM TRIS, 150 mM NaCl, 1% Triton X-100, pH 7.5)

• Gel electrophoresis and transfer:

  • Use 4-12% Bis-Tris gradient gels for optimal separation

  • Transfer to PVDF or nitrocellulose membranes using standard conditions

• Antibody incubation:

  • Block membranes thoroughly to reduce background

  • Incubate with anti-RHOBTB2 antibody at recommended dilutions (1:500-1:2000)

  • Incubate overnight at 4°C for optimal binding

  • Use appropriate HRP-conjugated secondary antibodies

• Detection and quantification:

  • Use ECL detection systems appropriate for your expected signal strength

  • Normalize to loading controls (α-tubulin or β-actin)

  • Quantify using densitometry (measure areas under peak corresponding to RHOBTB2 and normalize to loading control)

Note that endogenous RHOBTB2 may be difficult to detect in total cell lysates; immunoprecipitation prior to Western blotting may improve detection sensitivity .

How can RHOBTB2 antibodies be used to study protein-protein interactions?

RHOBTB2 antibodies can be used in multiple approaches to study protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate RHOBTB2 using specific antibodies (e.g., anti-cMyc for tagged constructs)

  • Immunoblot for interacting partners (e.g., CUL3, CCND1)

  • In the reversed approach, immunoprecipitate the suspected interacting protein and probe for RHOBTB2

  Protocol elements from published research:

  • Protein sample: 1.5 mg protein per sample adjusted to 300 μL with 1× TBS

  • Antibody: 1.6 μg anti-cMyc antibody

  • Beads: 20 μL Protein A Mag Sepharose bead suspension

  • Incubation: Overnight at 4°C

  • Controls: Beads only and beads with mouse IgG

• Proximity ligation assay (PLA):

  • Use RHOBTB2 antibodies in combination with antibodies against potential interacting proteins

  • Detect interactions as fluorescent spots indicating proximity (<40 nm)

• Immunofluorescence co-localization:

  • Perform double immunostaining with RHOBTB2 and interactor antibodies

  • Analyze co-localization patterns using confocal microscopy

These methods have been used to confirm RHOBTB2 interactions with Cullin3, E2F1, and CCND1, providing insights into its tumor suppressor function .

How can RHOBTB2 antibodies be used to investigate disease-associated mutations?

RHOBTB2 antibodies can be instrumental in studying disease-associated mutations through several methodological approaches:

• Expression level analysis:

  • Compare protein levels of wild-type vs. mutant RHOBTB2 in cellular models

  • Research has shown that certain missense variants (e.g., Y284D) lead to higher protein levels due to impaired proteasomal degradation

  • Protocol: Transfect cells with wild-type or mutant RHOBTB2, with or without proteasome inhibitor (MG-132), and analyze by Western blot

• Protein-protein interaction studies:

  • Investigate how mutations affect RHOBTB2 binding to CUL3 and other partners

  • Cancer-associated mutations in the first BTB domain (e.g., Y284D) have been shown to reduce CUL3 binding

  • Protocol: Co-transfect cells with HA-CUL3 and either wild-type or mutant RHOBTB2, immunoprecipitate RHOBTB2, and assess CUL3 binding by Western blot

• Subcellular localization:

  • Determine if mutations alter RHOBTB2 localization within cells

  • Use immunofluorescence with wild-type and mutant expressing cells

• Functional studies:

  • Investigate how mutations affect downstream pathways (e.g., Hippo signaling)

  • Compare the impact of different mutation classes (GTPase domain vs. BTB domain)

These approaches have revealed that RHOBTB2 variants impact protein stability and function differently depending on their location within the protein structure.

What are the methodological approaches to investigate RHOBTB2's role in neuronal development and epilepsy?

To investigate RHOBTB2's role in neuronal development and epilepsy, researchers can employ these methodological approaches:

• Patient-derived iPSC neuronal models:

  • Generate induced pluripotent stem cells (iPSCs) from patients with RHOBTB2 mutations

  • Differentiate into neurons and analyze for:

    • Electrophysiological parameters using whole-cell patch clamp recordings

    • Action potential firing patterns

    • Ion channel function

  • Research has shown neurons with BTB domain mutations display increased excitability compared to wild-type or GTPase domain mutants

• CRISPR/Cas9 engineered isogenic cell lines:

  • Create isogenic control and mutant lines to eliminate genetic background variability

  • Compare homozygous knockout versus heterozygous missense variants

  • Assess neuronal maturation, action potential parameters, and firing frequencies

• Animal models:

  • Drosophila models have demonstrated that RhoBTB knockdown in dendritic arborization neurons results in decreased dendrite numbers

  • Elevated RhoBTB levels in vivo correlate with seizure susceptibility and locomotor defects

• Transcriptomic analysis:

  • Examine how RHOBTB2 mutations affect expression of ion channel genes

  • Research in Drosophila suggested RhoBTB might contribute to transcriptional regulation of ion channel genes

These approaches have revealed distinct electrophysiological phenotypes associated with different RHOBTB2 variant classes, suggesting potential mechanisms for epileptogenesis in affected patients.

How can RHOBTB2 antibodies be used to investigate its tumor suppressor function?

Methodological approaches to investigate RHOBTB2's tumor suppressor function using antibodies include:

• Expression analysis in cancer tissues:

  • Compare RHOBTB2 protein levels between tumor and matched normal tissues

  • RHOBTB2 expression is decreased in breast, lung, bladder, bone, and gastric cancers

  • Use immunohistochemistry with validated anti-RHOBTB2 antibodies on tissue microarrays

• Colony formation and soft agar assays:

  • Deplete RHOBTB2 using shRNA in partially transformed cell models

  • Assess anchorage-independent growth capacity

  • Research has shown that RHOBTB2 knockdown increases colony formation in multiple cancer cell lines (HT-15, MDA-MB-468, HeLa, HCT116, and HT-29)

• YAP/Hippo pathway analysis:

  • Investigate RHOBTB2's role in regulating the Hippo tumor suppressor pathway

  • Assess YAP phosphorylation and nuclear localization after RHOBTB2 depletion

  • Measure expression of YAP target genes (CTGF, AREG, CYR61)

  • Protocol: Use three independent RHOBTB2 shRNAs and confirm knockdown by Western blot and qPCR

• Cyclin D1 regulation studies:

  • Examine how RHOBTB2 affects CCND1 levels and cell cycle progression

  • RHOBTB2 binds CCND1 through its first BTB domain and may downregulate this oncogenic protein

These approaches have revealed that RHOBTB2 functions as a tumor suppressor by recruiting proteins to the Cul3 ubiquitin ligase complex for degradation, potentially regulating cell cycle progression through CCND1 and influencing YAP/Hippo signaling.

How can I improve detection of endogenous RHOBTB2 in Western blots?

Endogenous RHOBTB2 can be challenging to detect in Western blots. To improve detection:

• Proteasome inhibition:

  • Treat cells with 5-25 μM MG-132 for 4-16 hours before lysate preparation

  • This prevents RHOBTB2 degradation, dramatically increasing protein levels

  • Published protocols have shown 4-fold increase in RHOBTB2 levels after MG-132 treatment

• Immunoprecipitation before Western blotting:

  • Enrich RHOBTB2 through immunoprecipitation

  • Use 1.5-2 mg of total protein for immunoprecipitation

  • Elute with SDS sample buffer containing DTT

• Membrane cutting and separate incubation:

  • Cut membranes and incubate RHOBTB2 and loading control antibodies separately

  • This reduces background and prevents interference between antibodies

• Signal amplification systems:

  • Use high-sensitivity ECL substrates

  • Consider biotin-streptavidin amplification systems

• Focus on tissues with known expression:

  • Neural tissues and rat lung have been identified as positive controls

These methods have been successfully applied in published research to detect endogenous RHOBTB2 that was otherwise undetectable in total cell lysates.

What are the common pitfalls in immunohistochemical detection of RHOBTB2?

Common pitfalls in immunohistochemical detection of RHOBTB2 and their solutions include:

• High background staining:

  • Cause: Insufficient blocking or nonspecific antibody binding

  • Solution: Extend blocking time (1-2 hours), use different blocking agents (BSA, serum, commercial blockers), and optimize antibody dilution (start with 1:50-1:200 as recommended)

• Weak or no signal:

  • Cause: Low RHOBTB2 expression, protein degradation, or epitope masking

  • Solution: Use antigen retrieval (citrate or EDTA-based), optimize antibody incubation time (overnight at 4°C), and consider signal amplification systems

• Nonspecific staining:

  • Cause: Cross-reactivity with related proteins

  • Solution: Use antibodies validated with knockout controls, perform peptide competition assays, and include proper negative controls in each experiment

• Inconsistent results:

  • Cause: Variations in fixation, processing, or antibody batch

  • Solution: Standardize tissue processing protocols, use positive control tissues in each run, and purchase sufficient antibody from the same lot for complete studies

• Misinterpretation of cellular localization:

  • Cause: RHOBTB2 localizes to multiple cellular compartments

  • Solution: Use co-staining with markers for specific cellular compartments (membrane, cytoskeleton, vesicles) to accurately interpret localization patterns

Published immunohistochemical analyses have successfully detected RHOBTB2 in tissues like human thyroid cancer using antibody dilutions around 1:30, suggesting that higher antibody concentrations may be needed for IHC compared to Western blotting .